C-WZUKMSC-derived extracellular vesicles, cell-free therapy, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game-changing weight loss drugs, the surging fascination with ADCs and hope for lower interest rates. But uncertainty looms about the upcoming general election in the U.S. and ground-shifting gene therapies. In a preview of the annual Biotech Showcase conference, an investor conference for private and micro- to mid-cap biotech companies Jan. 8-10 in San Francisco, BioWorld spoke with Dave Bearss, CEO of Halia Therapeutics Inc., Vimal Mehta, CEO of Bioxcel Therapeutics Inc., Paul Lammers, CEO at Triumvira Immunologics Inc., Chris Pirie, COO of HDT Bio Corp., Thijs Spoor, CEO of Perspective Therapeutics Inc. and Shelley Hartman, CEO of Aegle Therapeutics Corp. They offered insights brought about by years of hard-won experience. https://
Treatment of patients with deep second degree burns of the skin with extracellular vesicles (EV) isolated from bone marrow derived mesenchymal stem cells.
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Shelley Hartman, CEO Miami, FL (Private) AEGLE THERAPEUTICS Shelley Hartman, CEO Oct. 4 | 4:15pm | La Jolla Ballroom 2 Miami, FL (Private) Aegle Therapeutics is a regenerative medicine company isolating extracellular vesicles (EV) from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions including burns, scarring and epidermolysis bullosa. In April of 2018 the U.S. Food and Drug Administration (FDA) cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients. Aegle plans to file an additional IND for the treatment of EB later this year. http://www.aegletherapeutics.com
Quarterly report pursuant to Section 13 or 15(d) Cover Cover Financial Statements CONDENSED CONSOLIDATED BALANCE SHEET CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS EQUITY (DEFICIT) (UNAUDITED) CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED Notes to Financial Statements BASIS OF PRESENTATION REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES PROPERTY AND EQUIPMENT LEASES DEBT DEFERRED RD OBLIGATIONS PARTICIPATION AGREEMENTS STOCKHOLDER
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
News | Yourway Transport <img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif"> ASK FOR A QUOTE Biopharma Login Sign Up --> Tracking Contact MENU CLOSE About Company Leadership Quality Global Network Biopharma Services Clinical Supply Chain & Clinical Trial Logistics Clinical & Clinical Trial Packaging Packaging Design & Planning Primary Packaging Secondary Packaging Label Design & Translation Labeling, De-Labeling & Assembly Temperature-Controlled Packaging Comparator Drug & Ancillary Sourcin
2025 Coming Soon – Desert Liver Conference – Conquering Liver Disease Skip to content Home Conference Agenda Speakers Why Attend Why Attend Past Meeting Resources DLC 2024 DLC 2025 Sponsors 2027 Sponsorship Opportunities Coming Soon 2026 Sponsors Contact Accreditation Request for Credit 2025 Only Registration Home Conference Agenda Speakers Why Attend Why Attend Past Meeting Resources DLC 2024 DLC 2025 Sponsors 2027 Sponsorship Opportunities Coming Soon 2026 Sponsors Contact Accreditation Request for Credit 2025 Only Registration Home Conference Agenda Speakers Why Attend Why Atten
CHAICHADA CO.,LTD. - Online Guidebook | FOODEX JAPAN 2026 / 2026 Japan Meat Industry Fair 50th Online Guidebook DATE March 10 (Tue) - 13 (Fri), 2026 VENUE Tokyo Big Sight LOGIN JP Exhibitor's List Search Exhibitors Search Exhibit Products Invitation application form Visitor Pre-registration CHAICHADA CO.,LTD. https://chaichada.com/ Processed Food Booth number E7M03-016 Overseas exhibitors Exportable Co-exhibitor Organizer : Department of Industrial Promotion (DIPROM) Inquiry to exhibitor Chaichada is a Thai herbal company specializing in premium herbal teas, botanical extracts, and natural ing
Aegle Nutrition LLC H-1B & PERM Sponsorship Data | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support Aegle Nutrition LLC H-1B & Green Card Sponsorship Data Source: US Dept of Labor. Represents Base Salary only. Excludes RSUs, signing bonuses, and variable compensation. View All Salary Records Search for another employer Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only 1 Total Filings 2021-Present 100.0% Approva
Aegle LLC (Aegle LLC) - 药物管线_专利_临床试验_投融营收 产品 数据 资源 版本对比 预约演示 免费注册 更新于：2025-08-11 Aegle LLC 控股公司 | 2013 | Maryland, United States | < 10 | civisbank.com 控股公司 | 2013 | Maryland, United States | < 10 | civisbank.com 更新于：2025-08-11 概览 管线布局 药物交易 转化医学 营收 科研基金(NIH) 投资 融资 概览 关联 100 项与 Aegle LLC 相关的临床结果 登录后查看更多信息 0 项与 Aegle LLC 相关的专利（医药） 登录后查看更多信息 8 项与 Aegle LLC 相关的新闻（医药） 2025-07-15 · GlobeNewswire-Health Care Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board BOSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Aegle Therapeutics, a clinical-stage dermatology-focused … Healthcare Analyst and the Portfolio Manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein has been an operating partner at Aisling Capital since 2015. He currently serves on the board of directors for atai Life Sciences N.V., Caribou Biosciences, Inc., RAPT Therapeutics and Site One Therapeutics, a clinical-stage neurology company that is being acquired by Eli Lilly. Dr. Braunstein previously served on the board of directors of Trevena Inc., Esperion Therapeutics,
Overt Stop Loss: Innovative Stop-Loss Solution for Self-Funded Employers | Aegle Capital posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
AGLE-102 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 AGLE-102 Last update 08 May 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Exosomes Synonyms Extracellular vesicle therapy Aegle Therapeutics, MSC EVs Aegle Therapeutics + [2] Target COL7A1 Action modulators Mechanism COL7A1 modulators(Collagen alpha-1(VII) chain modulators) Therapeutic Areas Congenital Disorders Skin and Musculoskeletal Diseases Other Dise
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
AEGLE THERAPEUTICS News - Recent Updates & Announcements × Member Login Library Shopping Cart --> Username Password Remember Me Forgot password/Login issues? Not a Member? Learn more . Blog Partnership Contact Cart (0) Member Login Solution Membership Academic Corporate Market Research Custom Research Company Index Scorecard Industries Life Sciences Med Devices & Surgical Cell Biology Pharmaceuticals Health Maintenance Digital World Instrumentation and Sensors Safety and Security Engineering Photonics Information Technology Materials Advanced Materials Plastics Chemical
Venture Capital Portfolio | DeepWork Capital | Florida Home About Us Portfolio Florida Opportunity Fund News Contact Us Careers Investor Login Home About Us Portfolio Florida Opportunity Fund News Contact Us Careers Investor Login OUR PORTFOLIO We partner with visionary entrepreneurs with integrity and grit to build disruptive companies. The entrepreneurs and their team are always at the center of what we do. AbFero Pharmaceuticals Therapeutics for iron overload Boston, MA Acquired by Pharmacosmos Button Astrocyte Pharmaceuticals Therapeutics for brain injury Groton, CT Button Aegle Ther … platform Seattle, WA Acquired by Chronus Button Lucy Labs Cryptocurrency hedge fund Las Vegas, NV Button Intecrowd Workday partner & consultancy Orlando, FL Acquired by Clearsight Advisors, Inc. Button LUMU Enterprise software cybersecurity platform Doral, FL Button Intelligent Observation Healthcare information technology that allows hospital facilities to increase hand hygiene compliance Miami, FL Acquired by HID Global Button Mobilo The smarter way to network New York
Aegle Care Inc - Historical report for H1B visa and greencard sponsorship applications "> Welcome, Guest Login Register for Free! Immihelp Welcome, Guest Login Register for Free! Home Greencard Visas Insurance Experiences Forum Tracker USA Travel NRI Tools Blog Select Language For visitors, travel, student and other international travel medical insurance. Visit insubuy.com or call +1 (866) INSUBUY or +1 (972) 985-4400 Home » AEGLE CARE INC » Applications Print Share Facebook X LinkedIn WhatsApp Email Share on Facebook X LinkedIn WhatsApp Email Employer Explore more Home - H1B Sponsors Ho
Aegle Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment … ls , DEFTA Partners and 1 other • Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa PR Newswire • Jan 07, 2020 • Aegle Therapeutics , New World Angels , DEFTA Partners , DeepWork Capital and 1 other • Aegle Therapeutics Corp. Receives IND Clearance from FDA for Stem Cell-Derived Extracellular Vesicle Therapy for Burns PRWeb • May 11, 2018 • Aegle Therapeutics Get curated
Aegle Aviation granted Aruban AOC | Corporate Jet Investor | CJI news Skip to the content About Contact Advertise and Sponsor Search Search Menu News Topics Aircraft – News, analysis, data and buyer’s guides to business aircraft and aircraft manufacturers. Business/Industry – The business of business aviation – includes articles looking at investment in business aviation; mergers and acquisitions; and finance Buying – Content focused on the buying, selling and financing of business jets. Flying – Everything involved in flying by business jet – including charter, FBOs, private jet t
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
#yearinreview #aeglecapital #partnerships #innovation #stoploss | Aegle Capital LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User A … • Main Capital Partners to acquire xxllnc via a €300m single-asset continuation fund • Teleo-backed Softrax acquired BluLogix • Itron to acquire Energize Capital -backed Urbint for $325m • GenNx360 Capital Partners acquired Heartland Business Systems • Godspeed Capital Management to sell SilverEdge to SAIC for $205m • Triple Private Equity-backed SmartSearch bought Credas Technologies • EQT Group Ventures made a €50m investment in AI platform Harvey • General Atlantic and La … t picked up Omega3C • ECI Partners reinvested in CSL via its first continuation fund • Bridgepoint Group invested in SaaS provider Chime Construction Software 🔹 Three clear trends stand out: 1️⃣ AI and data-driven investments continue to lead capital allocation. 2️⃣ Continuation funds have become a core liquidity strategy across the mid-market. 3️⃣ Specialized sector focus — from govtech to energy and compliance — is defining 2025’s deal flow. The PE market may be discipline … week’s HealthVC breaks down how to build a company that investors actually can fund: • The pre- vs post-money trap that quietly kills ownership • Rights investors respect — and the ones that make them run • Option pool math that stops you paying the phantom tax • Governance that won’t haunt your Series A • The one-page cap table that passes diligence on first read If you can explain your ownership clearly, you can raise confidently. 👉 Read the full masterclass inside Health … y without the traditional Angel/VC risk! Shift 20% of your budget here and keep rolling the "line of credit over" to the next projects. Here’s the truth: every day you delay, millions in documented, recoverable revenue are left on the table. Others will claim it first. If you’re serious about high-upside acquisitions, safe growth, and impact that
Evaluation of the Effect of Aegle marmelos (Bael Leaf) Extract on Human Fibroblast Viability: An In Vitro Study | Cureus Home Specialties Specialties Browse Articles Posters Abstracts Cureus Collections Specialties Allergy / Immunology Anatomy Anesthesiology Cardiac / Thoracic / Vascular Surgery Cardiology Dentistry Dermatology Emergency Medicine Endocrinology / Diabetes / Metabolism Environmental Health Epidemiology / Public Health Family / General Practice Forensic Medicine Gastroenterology General Surgery Genetics Geriatrics Healthcare Technology Health Policy Hematology HIV / AIDS Infectio … Cureus Journal of Medical Science Cureus China Cureus Japan Cureus New Authors SUBMIT RESEARCH SIGN IN JOIN NOW Cureus Journal of Medical Science Cureus Journal of Medical Science Cureus China Cureus Japan Cureus New Authors Specialties Browse Articles Posters Abstracts Cureus Collections Specialties More Allergy / Immunology Anatomy Anesthesiology Cardiac / Thoracic / Vascular Surgery Cardiology Dentistry Dermatology Emergency Medicine Endocrinology / Diabetes / Metabolism … otion Management on Helical and Robotic RT Platforms Sponsored by Accuray, Inc. SUBMIT RESEARCH SIGN IN JOIN NOW Home Browse Specialties Therapeutics Article Enter your email address to receive your free PDF download. Please note that by doing so you agree to be added to our monthly email newsletter distribution list. New here? Sign up. Sign in to Cureus sign in using LinkedIn sign in using Google sign in using Facebook or Sign in with your email address: Email Password Don't … be used to enrich the user experience and contact you in direct relation to the application. I agree to opt in to this communication. By joining Cureus, you agree to our Privacy Policy and Terms of Use . Download Cureus Media Kit I would like to receive Cureus newsletters and updates. Published Content Specialties Articles Posters Abstracts Collections Channels Competitions Resources Cureus Guides Cureus Honors Author Fees SIQ Article Promotion Advertising Policy Advertise Wi
Aegle Therapeutics Corp. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 06 Mar 2026 Aegle Therapeutics Corp. Holding Company | 2013 | Florida, United States | < 10 | www.aegletherapeutics.com Holding Company | 2013 | Florida, United States | < 10 | www.aegletherapeutics.com Last update 06 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Aegle Therapeutics is a private biotech firm that is creating a pioneering therapy usin … lthcare Analyst, and the Portfolio Manager of the J.P. Morgan Global Healthcare Fund. “Ray Therapeutics has a truly unique opportunity to usher in a new generation of bioengineered optogenetic medicines for those with blinding diseases,” said Dr. Braunstein. “I am impressed by the scientific rigor behind RayTx’s programs and the management team’s commitment to patient outcomes. I look forward to working with the executive leadership team and the Board on a variety of strategi … Healthcare Analyst and the Portfolio Manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein has been an operating partner at Aisling Capital since 2015. He currently serves on the board of directors for atai Life Sciences N.V., Caribou Biosciences, Inc., RAPT Therapeutics and Site One Therapeutics, a clinical-stage neurology company that is being acquired by Eli Lilly. Dr. Braunstein previously served on the board of directors of Trevena Inc., Esperion Therapeutics, … for use in DEB patients aged six months and older. The Marketing Authorization Application (MAA) for VYJUVEK has been validated by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is currently under review. JACE, developed by Japan Tissue Engineering, is a combination product featuring a human autologous epidermal cell sheet created using Green's technique. In December 2018, Japan's Ministry of Health, Labour and Welfare (MHLW) … tly the only FDA-approved therapy for RDEB wounds that works with just a single application. The approval was granted based on results from the Phase III VIITAL study (NCT04227106), a multi-center, randomized, intrapatient-controlled trial. The study successfully met its two main goals, showing significant wound healing (50% or more from baseline
AEGLE CARE INC,(D/B/A LUMIRADX) H-1B & PERM Sponsorship Data | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support AEGLE CARE INC,(D/B/A LUMIRADX) H-1B & Green Card Sponsorship Data Source: US Dept of Labor. Represents Base Salary only. Excludes RSUs, signing bonuses, and variable compensation. View All Salary Records Search for another employer Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only 0 Total Filings 202
Sponsorship: Fourth Annual Primary Care MASLD/MASH Summit 2025 Menu Fourth Annual Primary Care MASLD/MASH Summit 2025 Home Committee Program Sponsorship Newsletter Register EUROPEAN PC MASLD/MASH SUMMIT SPONSORSHIP Thank you to our sponsors Novo Nordisk Canada Gold Boehringer-Ingelgeim (Canada) Ltd. Bronze Aegle Medical Solutions | Mindray Friends 89bio, Inc. Supporter Eli Lilly Canada Supporter GSK Canada Supporter Sentrex Health Solutions Supporter Siemens Healthineers Supporter It is imperative that Primary Care Physicians and allied health professionals in Canada are equipped with the know
Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Clinical Trial Administering a Novel Extracellular Vesicle Therapy | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Aegle Therapeutics Corp - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
We're excited to welcome Pete... - MSU Research Foundation Facebook Log In MSU Research Foundation's Post MSU Research Foundation November 19, 2024 · Shared with Public We're excited to welcome Pete Martin as our new Director of Portfolio Management! Pete is a former venture-backed founder with a passion for helping startups scale and succeed. Drawing on his entrepreneurial experience, he'll work closely with our portfolio companies to guide their growth and position them for successful exits. Known for his positive attitude, and hands-on approach, Pete is dedicated to buil
Frontiers | Mesenchymal Stromal Cells and Exosomes: Progress and Challenges Frontiers in Cell and Developmental Biology About us About us Who we are Mission and values History Leadership Awards Impact and progress Frontiers' impact Our annual reports Thought leadership Publishing model How we publish Open access Quality and research integrity Peer review Research Topics Publish your data Fee policy Services Societies National consortia Institutional partnerships Collaborators More from Frontiers Frontiers Forum Frontiers Planet Prize Press office Sustainability Career opportunities Contact … office Sustainability Career opportunities Contact us All journals All articles Submit your research Search Frontiers in Cell and Developmental Biology Sections Sections Cancer Cell Biology Cell Adhesion and Migration Cell Death and Survival Cell Growth and Division Cellular Biochemistry Chromosome and Chromatin Biology Embryonic Development Evolutionary Developmental Biology Membrane Traffic and Organelle Dynamics Molecular and Cellular Pathology Molecular and Cellular Repro … rnal sections Open access statement Copyright statement Quality For authors Why submit? Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office About us About us Who we are Mission and values History Leadership Awards Impact and progress Frontiers' impact Our annual reports Thought leadership Publishing model How we publish Open access Quality and research integrity Peer review Research Topics Publish your data Fee p … partnerships Collaborators More from Frontiers Frontiers Forum Frontiers Planet Prize Press office Sustainability Career opportunities Contact us All journals All articles Submit your research Frontiers in Cell and Developmental Biology Sections Sections Cancer Cell Biology Cell Adhesion and Migration Cell Death and Survival Cell Growth and Division Cellular Biochemistry Chromosome and Chromatin Biology Embryonic Development Evolutionary Developmental Biology Membrane Traffic … rnal sections Open access statement Copyright statement Quality For authors Why submit? Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office Frontiers in Cell and Developmental Biology Sections Sections Cancer Cell Biology Cell Adhesion and Migration Cell Death and Survival Cell Growth an
Aegle Capital | Hyde Park Venture Partners Job Board WHO WE Are COMPANIES JOBS PERSPECTIVES NEWSLETTER WHO WE Are COMPANIES JOBS PERSPECTIVES NEWSLETTER WHO WE Are COMPANIES JOBS PERSPECTIVES NEWSLETTER WHO WE Are COMPANIES JOBS PERSPECTIVES NEWSLETTER Make your next big move companies Jobs Search jobs Explore companies Join talent network Talent My job alerts Aegle Capital aeglecap.com Locations Minneapolis, MN, USA · New York, NY, USA industry Finance · Financial Services · Funding Platform · Risk Management Size 11 - 50 employees Stage Other founded i
Aegle Therapeutics Names Industry Veteran Scott Braunstein, --> Accessibility: Skip TopNav Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board July 15, 2025 10:00 ET | Source: Aegle Therapeutics Aegle Therapeutics BOSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, today announced the appointment of Scott Braunstein, M.D., as Chairman of the Board. The company’s lead product candidate AGLE-102, a co … Healthcare Analyst and the Portfolio Manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein has been an operating partner at Aisling Capital since 2015. He currently serves on the board of directors for atai Life Sciences N.V., Caribou Biosciences, Inc., RAPT Therapeutics and Site One Therapeutics, a clinical-stage neurology company that is being acquired by Eli Lilly. Dr. Braunstein previously served on the board of directors of Trevena Inc., Esperion Therapeutics,
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Portfolio Companies — News from Florida angel investors — New World Angels 0 Skip to Content About About NWA NWA Members News Portfolio Entrepreneurs Investors Innovation Fund About Innovation Fund Innovation Fund Funding Incubators & Accelerators Blog APPLY FOR FUNDING Open Menu Close Menu About About NWA NWA Members News Portfolio Entrepreneurs Investors Innovation Fund About Innovation Fund Innovation Fund Funding Incubators & Accelerators Blog APPLY FOR FUNDING Open Menu Close Menu Folder: About Back About NWA NWA Members News Portfolio Entrepreneurs Investors Folder: I … About NWA NWA Members News Portfolio Entrepreneurs Investors Folder: Innovation Fund Back About Innovation Fund Innovation Fund Funding Incubators & Accelerators Blog APPLY FOR FUNDING News Stay up to date with the latest news, investments, portfolio updates, and industry recognition. 100+ Active Investors $30M+ Invested South Florida Based, Global Reach. FEATURED NEWS News June 24, 2026 New World and University of Central Florida Establish Strategic Collaboration to Adva … vests another $872,500 into Clarke in Q3 Read More Looking to build the future? APPLY FOR FUNDING We partner with visionary founders to build category-defining companies. MEMBERSHIP You will be redirected to Dealum, our funding application platform Join Our Mailing List News Terms of Use Privacy Policy COPYRIGHT © 2024 NEW WORLD ANGELS No results found
Privacy Policy - AEGLE Therapeutics Company EV Therapy Pipeline News Contact Privacy Policy AEGLE Therapeutics (“Aegle”, “we”, “us”, “our”) respects the privacy of all individuals who visit www.aegletherapeutics.com (the “Website”). This Privacy Policy contains important information regarding the collection, use and disclosure of information that identifies, relates to, describes, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a natural person or household, such as a name, postal address, e-mail address, or telephone number (“Persona … as your name, address, telephone number, or e-mail address) when you choose to submit it to us through our contact page. If you contact us by sending us an e-mail, we may collect any information that is contained in and/or attached to your e-mail. We may use the information that you provide us to respond to your inquiry. Information Disclosure We do not share your Personal Information with any third parties. In the event Aegle goes through a business transition such as … . If you are under the age of 18, you should not use this Website or submit any Personal Information to this Website. If we receive Personal Information that we discover was provided by a child under the age of 18, we will attempt to delete the information as soon as possible. Do Not Track Do Not Track is a preference you can set on your browser to inform websites that you do not want to be tracked. We do not support Do Not Track (“DNT”). You can either enabl
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
About - Tellus BioVentures About Portfolio News Contact About Portfolio News Contact Mission Team Mission To uncover and accelerate promising life science innovation Important scientific discoveries at academic centers, research entities and on the shelves of biopharmaceutical companies often languish without the necessary resources and prioritization for further advancement. We look to uncover these high-potential assets and surround them with the right team and capital resources to turn them into life-changing therapeutics. To enable talented entrepreneurs and innovators We believe that entr … aceutical experts advise and assist in the management of the Tellus BioVentures fund and formally engage in the governance and/or operational management of portfolio companies. These Advisors consist of individuals with senior level R&D and business experience and experts in various technical disciplines including Clinical Development, Manufacturing/CMC, Regulatory Affairs, Toxicology, DMPK, Program Management and Business Development. About Portfolio News Contact 10831 I
Exosome-Based Therapeutic Development Summit 2024 — The Pharma Navigator - Navigating The Key News Stories In Pharma 0 Skip to Content News Previous Issues Podcast About Events Advertise Contact Subscribe Open Menu Close Menu News Previous Issues Podcast About Events Advertise Contact Subscribe Open Menu Close Menu News Previous Issues Podcast About Events Advertise Contact Subscribe Back to All Events Exosome-Based Therapeutic Development Summit 2024 Tuesday 17 September 2024 07:00 Thursday 19 September 2024 18:00 Boston USA (map) Google Calendar ICS Now more than ever, exosome and extr
Synergistic Potential Of Aegle Marmelos Essential Oil In Combination With Antifungal Drugs Against Drug Resistant Fungal Pathogens | Infectious Diseases Conferences | Infectious Disease Conferences 2026 | Infectious Disease Conference | Infectious Disease Conference 2026 | Infectious Diseases Congress 2026 | Infectious Diseases Congress | Infectious Diseases Events | Infectious Diseases Events | Infectious Diseases Meetings 4 th International Conference on Infectious Diseases September 09–10, 2026 | Virtual Event Virtual Event Scitechseries Publishing Limited --> Email: infectiousdisease@scite … Q Important Dates Conference Brochure About Past Events About Organizer Contact Submit Abstract Register Infectious Diseases 2026 Home Scientific Program Riya Bhattacharya Woxsen University, India Title : Synergistic potential of Aegle marmelos essential oil in combination with antifungal drugs against drug resistant fungal pathogens. Abstract: Drug resistance among fungal infections has increased in recent years and the efficacy of antibiotics has declined. By combining anti … build global collaborations. Quick Links Scientific committee Speakers Contact Submit abstract Register Program Information Testimonials Contact Us Scitechseries Publishing Limited 71-75, Shelton, Covent Garden London, WC2H 9JQ Email: [email protected] Phone: +44 2045874848 WhatsApp: +44 7383507342 Email: [email protected] Office: +44 2045874848 WhatsApp: +44 1407380045 --> Sponsor/Exhibition: Email: [email protected] &
%PDF-1.3 %��������� 4 0 obj > stream xŝ{���q��ǧ�MHܣ| �ʊ7w$m�}�/�DJL9vTv ���RR���� �����sE����zz��=�%}H������L��.-���}ES�W��[����}�c>�M�~�Mz�.m*ׅ���q �n(�wߤ/߽�1}��t����ݟ�7��Hg��.�軯�0B=�y�Mz]UU� ��t��g�G�t]����y����~����'|/�D~����k�mj���t���% U�{1�Z]�_���ΛArL�� �vh�%�w����E��E=.ζ��|��r049��ƞ� ̜��P�̦\D f6��H�?��a��o��'FM�{�8�����o|5kLvY�i�����^�M�w���i�/�,���ѧn,ʱ+�ֺ�2=C�"��U���0� v�k��qMm}9�C��Qn[UZ�7-�s��-[�!��,Zچ���o+`^�>�%.�6 G]&�u��e�&�"6�`\y-nV��y� �M)���>7ic\AJ��y[�^�1D; z=6� ��J�mG�Z�5�#@O�XW�V�M�tH�rW=m� 6�ٖ�� EV�� ��nF�`������������3����Z��_� �2�
Bael (Aegle marmelos) - Online Guidebook | FOODEX JAPAN 2026 / 2026 Japan Meat Industry Fair 50th Online Guidebook DATE March 10 (Tue) - 13 (Fri), 2026 VENUE Tokyo Big Sight LOGIN JP Exhibitor's List Search Exhibitors Search Exhibit Products Invitation application form Visitor Pre-registration Bael (Aegle marmelos) Baked Goods Cakes / Dessert Bread Japanese sweets Gluten-free Chocolate Bottled Water Candy Carbonated Soft Drinks Coffee Energy Drinks Flavoured Water Instant Beverages Juice Non-alcoholic Beverages Smoothies Tea Dried Fruit & Vegetables Target Sector Restaurant, Supermarket, H
New World Angels Invests $697K in Aegle Therapeutics' Clinical Trials — New World Angels 0 Skip to Content About About NWA NWA Members News Portfolio Entrepreneurs Investors Innovation Fund About Innovation Fund Innovation Fund Funding Incubators & Accelerators Blog APPLY FOR FUNDING Open Menu Close Menu About About NWA NWA Members News Portfolio Entrepreneurs Investors Innovation Fund About Innovation Fund Innovation Fund Funding Incubators & Accelerators Blog APPLY FOR FUNDING Open Menu Close Menu Folder: About Back About NWA NWA Members News Portfolio Entrepreneurs Investo … About NWA NWA Members News Portfolio Entrepreneurs Investors Folder: Innovation Fund Back About Innovation Fund Innovation Fund Funding Incubators & Accelerators Blog APPLY FOR FUNDING New World Angels Invests $697K in Aegle Therapeutics' Clinical Trials Press Investments Portfolio Companies Mar 4 Written By Adriana Salcedo BOCA RATON, FL (March 4, 2025) – New World Angels (“NWA”) a leading Florida-based structured angel capital investment organization, announced today th … sease. Additionally, Aegle has compelling safety and efficacy data from a grant-supported proof-of-concept deep second-degree burn trial. In December 2024, Aegle launched a $3MM Convertible Note Series to fund the completion of the DEB trial as well as other operations through 2025. “Support from key investors, including NWA, has been critical to Aegle’s advancement into the clinic and to the generation of compelling, early patient data,” said Shelley Hartma
AEGLE THERAPEUTICS News - Recent Updates & Announcements × Member Login Library Shopping Cart --> Username Password Remember Me Forgot password/Login issues? Not a Member? Learn more . Blog Partnership Contact Cart (0) Member Login Solution Membership Academic Corporate Market Research Custom Research Company Index Scorecard Industries Life Sciences Med Devices & Surgical Cell Biology Pharmaceuticals Health Maintenance Digital World Instrumentation and Sensors Safety and Security Engineering Photonics Information Technology Materials Advanced Materials Plastics Chemical
Shelley Hartman - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailing … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Aegle Pharma - Disruptive Doctors® Skip to content Download App DD CON 2026 DD CON 2026 About DD DD App Our Story Resources All Academy Workshops Articles Podcast Videos Resume Writing for Doctors e-Book on Switching Careers for Doctors Opportunities Job Openings Secondary Income Careers With Disruptive Doctors H Innovators Solutions GP Clinic Solutions Hub Top Non-Clinical Healthcare Programmes For Doctors Specialty Medicine Certification Hub For Businesses For Businesses DD CON 2026 Exhibitor / Sponsor Sign In Menu DD CON 2026 DD CON 2026 About DD DD App Our Story Resources All Academy Works
Phase 1/2A Clinical Trial of AGLE-102 for RDEB | debra of America Skip to main content Home Top Menu For Medical Professionals Donate Donate Donate Search Debra For Medical Professionals Clinical Management of EB HCP Engagement & Events Order Free EB Patient Resources Patient Referral for EB Support debra EB Physician Directory About Us What We Do Meet the Team DEBRA International Annual Reports & Financials Media Center Contact Us About EB Understanding EB EB Simplex Dystrophic EB Junctional EB Kindler EB Getting Diagnosed Clinical Trials Approved Treatments Personal Stories Video Sto … lp Emergency Care Wound Care Distribution EB Nurse New Families Legal Aid Smile Fund Mentorships debra Care Conference EB Doctor Directory Connect with Others Other Resources Travel Social Story for EB Doctor Visits: A Guide for Kids School Resources EB Camps EB Cards Bereavement Medical Supply Companies Get Involved Ways to Give Fundraise Host a Supporter Led Event Government Advocacy Internship Volunteer Share Your Story Purchase with Purpose Subscribe to Emails Events debr … lp Emergency Care Wound Care Distribution EB Nurse New Families Legal Aid Smile Fund Mentorships debra Care Conference EB Doctor Directory Connect with Others Other Resources Get Involved Ways to Give Fundraise Host a Supporter Led Event Government Advocacy Internship Volunteer Share Your Story Purchase with Purpose Subscribe to Emails Events debra-Hosted Events Supporter Led Events TEAM DEBRA Endurance Events Awareness & Advocacy Events
Aegle Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Aegle Therapeutics Website: Aegle Therapeutics Business Area(s) Exosomes Stem Cells Regenerative Medicine Therapeutics Description Aegle Therapeutics develops cell-free therapies using extracellular vesicles (exosomes), isolated from mesenchymal stems cells, to deliver drugs to treat disorde
AEGLE SAFETY EQUIPMENTS (SHANGHAI) CORP,LTD. --> --> --> Add to your calendar --> --> --> --> Register as Visitor Visitor Login --> --> Booth Application --> Visitor Login --> Visitor Login --> Add to your calendar --> Search Popular search terms CIOSH 2022 how to arrive contact us download 中文 日本語 --> 한국어 --> ไทย --> China International Occupational Safety & Health Goods Expo 13-15 APRIL 2023 丨 SHANGHAI, CHINA --> China International Occupational Safety & Health Goods Expo 14-16 APRIL 2027 丨 SHANGHAI, CHINA --> Countdown: Days . Hours : Min : Sec China International Occupational Safety & Healt … > Register as Visitor --> Register as Visitor --> Register as Visitor --> Booth Application --> Booth Application Booth Application --> --> Online registration will start soon！ OK Search for Exhibitors AEGLE SAFETY EQUIPMENTS (SHANGHAI) CORP,LTD. --> --> --> 微信扫一扫：分享 --> --> --> --> --> 微信里点“发现”，扫一下 --> 二维码便可将本文分享至朋友圈。 --> --> --> AEGLE SAFETY EQUIPMENTS (SHANGHAI) CORP,LTD. Booth Number：1C51 www.aegle.com.cn Product Category: All Range of PPE --> 预约展商 --> 收藏展商 --> --> --> ww … 2021-04-14 (Wednesday) 2021-04-15 (Thursday) 2021-04-16 (Friday) Time： A.M P.M Submit --> Visitor Login --> --> --> --> 我是展商 I AM AN EXHIBITOR --> --> --> --> --> --> 我是观众 I AM A VISITOR --> --> --> --> --> --> --> --> --> Login Organizer China Textile Commerce Association Strategic Partner Messe Düsseldorf (Shanghai) Co., Ltd. Fair Management CIOSH Asia (Beijing) Co., Ltd. 战略合作伙伴 --> Contact Us Messe Düsseldorf (Shanghai) Co., Ltd. Tel: +86-21-6169 8386 Email:
Aegle Therapeutics Jobs + Careers | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Aegle Therapeutics Teams Aegle Therapeutics Save Saved Miami 2 Total Employees View Website Overview Jobs Offices Is This Your Company? Claim Profile Jobs at Aegle Therapeutics Let Your Resume Do The Work Upload your resume to be matched with jobs you're a great fit for. Upload Resume Success! We'll use this to further personalize your experience. No jobs to discover at this time. back to overview Jobs at similar companie
News - AEGLE Therapeutics Company EV Therapy Pipeline News Contact News Stay up to date on Aegle updates and publications. Company Updates 07/15/2025: Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board Learn More 08/14/2024: Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102 ™ in Patients with Dystrophic Epidermolysis Bullosa (“DEB”) Learn More 03/25/2024: Aegle’s Phase 1/2a clinical trial of AGLE-102 ™ in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollm … horrific pediatric disorder Learn More 10/08/2020: Aegle Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of AGLE-102 Learn More 10/06/2020: Aegle Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa Learn More 10/01/2020: FDA Grants Fast Track Status to Aegle T … Financing Learn More 01/07/2020: Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa Learn More 01/07/2020: Aegle Therapeutics welcomes Elona Baum, Lonnie Moulder and David Schimel to its Board of Directors Learn More 08/09/2019: Aegle Wins Debra’s Partners in Progress Award, Plans to Soon Open Clinical Trial in DEB Patients Learn More 05/20/2019: Aegle Therapeutics Corp. … nistration (FDA) has cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients. Aegle expects to initiate a Phase 1/2a clinical trial of AGLE-102 for the treatment of severe burn patients in late 2018 Learn More 04/10/2018: Aegle Therapeutics researchers publish Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts
Clinical Trial Update: First Patient Dosed in Phase 1/2a Trial of AGLE-102 in DEB - The Dermatology Digest Skip to content Subscribe Search Search Home News Videos Conference Coverage Podcasts Resource Centers Acne Alopecia Atopic Dermatitis Cosmetics Hidradenitis Suppurativa (HS) Pediatrics Pigment Disorders Practice Management Psoriasis Rare Diseases Rosacea Skin Cancer Vitiligo Home News Videos Conference Coverage Podcasts Resource Centers Acne Alopecia Atopic Dermatitis Cosmetics Hidradenitis Suppurativa (HS) Pediatrics Pigment Disorders Practice Management Psoriasis Rare Diseases Rosacea
AEGLE Therapeutics | DeepWork Capital Job Board Home About Us Portfolio Florida Opportunity Fund News Contact Us Careers Home About Us Portfolio Florida Opportunity Fund News Contact Us Careers DeepWork Portfolio Careers Build With Us 0 COMPANIES 0 JOBS Search jobs Explore companies Join talent network Talent My job alerts AEGLE Therapeutics aegletherapeutics.com Locations Miami, FL, USA · Woburn, MA, USA Size 1 - 10 employees Stage Other founded in 2013 Socials LinkedIn Crunchbase Twitter About Aegle Therapeutics is a privately-held biotechnology company developing a first in class therapy us
#biofuture2025 #demycolton #biotech #biopharma #ai #ml #medtech #lifesciences #healthcareinnovation #futureofhealthcare | Demy-Colton LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Conti
BioWorld. Link to homepage. | Christopher Pirie LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and
Aegle Therapeutics CEO Shelley A. Hartman joined BioWorld and other biopharma executives to discuss 2023 challenges and opportunities for the year ahead. Check out the insightful podcast!… | Aegle Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any t
Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developme … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa January 7, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular … //www.prnewswire.com/news-releases/aegle-therapeutics-announces-4m-financing-to-fund-groundbreaking-stem-cell-exosome-clinical-trial-to-treat-orphan-disease-dystrophic-epidermolysis-bullosa-300982886.html SOURCE Aegle Therapeutics Corp. Twitter LinkedIn Facebook Email Print NextGen: Class of 2026 LATEST Mergers & acquisitions BIO 2026: Forget dual track—biopharma deals are more complex than ever June 25, 2026 · 4 min read · Annalee … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
2026 debra of America Gala | debra of America Skip to main content Home Top Menu For Medical Professionals Donate Donate Donate Search Debra For Medical Professionals Clinical Management of EB HCP Engagement & Events Order Free EB Patient Resources Patient Referral for EB Support debra EB Physician Directory About Us What We Do Meet the Team DEBRA International Annual Reports & Financials Media Center Contact Us About EB Understanding EB EB Simplex Dystrophic EB Junctional EB Kindler EB Getting Diagnosed Clinical Trials Approved Treatments Personal Stories Video Stories News & Blog … lp Emergency Care Wound Care Distribution EB Nurse New Families Legal Aid Smile Fund Mentorships debra Care Conference EB Doctor Directory Connect with Others Other Resources Travel Social Story for EB Doctor Visits: A Guide for Kids School Resources EB Camps EB Cards Bereavement Medical Supply Companies Get Involved Ways to Give Fundraise Host a Supporter Led Event Government Advocacy Internship Volunteer Share Your Story Purchase with Purpose Subscribe to Emails Events debr … lp Emergency Care Wound Care Distribution EB Nurse New Families Legal Aid Smile Fund Mentorships debra Care Conference EB Doctor Directory Connect with Others Other Resources Get Involved Ways to Give Fundraise Host a Supporter Led Event Government Advocacy Internship Volunteer Share Your Story Purchase with Purpose Subscribe to Emails Events debra-Hosted Events debra Care Conference Supporter Led Events TEAM DEBRA Endurance Events Awareness & Advocacy Events
Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle Therapy Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-onl … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Portal - Live Events Exhibitors Aegle Medical Solutions Aegle Medical is the exclusive distributor of the NexGen Transient Elastography technology (ViTE) from Mindray called the Hepatus which is an alternative technology to Fibroscan. https://aeglemedicalsolutions.com/ Ipsen Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing medicines in three key therapeutic areas – Oncology, Rare Disease and Neuroscience. We are dedicated to providing hope for peopl
Pipeline - AEGLE Therapeutics Company EV Therapy Pipeline News Contact Pipeline Aegle is developing novel therapies using bone marrow mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) to treat disorders with significant unmet medical need. Our proprietary EV harvesting technology has the potential to develop therapies in multiple therapeutic areas. We are initially developing AGLE-102 TM as a first-in-class therapy for a rare, monogenetic, pediatric disease called dystrophic epidermolysis bullosa (DEB). Aegle’s Phase 1/2 clinical trial involving AGLE-102 in individua … h a strong safety and activity profile for AGLE-102. This trial was funded by a grant from the Department of Defense. More information regarding the trial can be found on ClinicalTrials.gov . Additional Indications Aegle’s platform EV harvesting technology has the potential to treat a wide range of other therapeutic indications. Preclinical animal models have produced compelling data supporting the use of AGLE-102 for Graft vs. Host Disease prophylaxis. We are also evaluating
Sponsor Details: Fourth Annual Primary Care MASLD/MASH Summit 2025 x Sponsor Details Name Aegle Medical Solutions | Mindray Sponsorship Level Friends Description At Aegle Medical, our mission is to empower clinicians with emerging technologies that drive better care. Through cutting-edge medical equipment and smart software solutions, we help improve clinical confidence, diagnostic accuracy, and patient satisfaction. https://aeglemedicalsolutions.com/ https://www.mindray.com/en Website https://www.mindray.com/en Close
Aegle Therapeutics Corp. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 06 Mar 2026 Aegle Therapeutics Corp. Holding Company | 2013 | Florida, United States | < 10 | www.aegletherapeutics.com Holding Company | 2013 | Florida, United States | < 10 | www.aegletherapeutics.com Last update 06 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Aegle Therapeutics is a private biotech firm that is creating a pioneering therapy usin … lthcare Analyst, and the Portfolio Manager of the J.P. Morgan Global Healthcare Fund. “Ray Therapeutics has a truly unique opportunity to usher in a new generation of bioengineered optogenetic medicines for those with blinding diseases,” said Dr. Braunstein. “I am impressed by the scientific rigor behind RayTx’s programs and the management team’s commitment to patient outcomes. I look forward to working with the executive leadership team and the Board on a variety of strategi … Healthcare Analyst and the Portfolio Manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein has been an operating partner at Aisling Capital since 2015. He currently serves on the board of directors for atai Life Sciences N.V., Caribou Biosciences, Inc., RAPT Therapeutics and Site One Therapeutics, a clinical-stage neurology company that is being acquired by Eli Lilly. Dr. Braunstein previously served on the board of directors of Trevena Inc., Esperion Therapeutics, … for use in DEB patients aged six months and older. The Marketing Authorization Application (MAA) for VYJUVEK has been validated by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is currently under review. JACE, developed by Japan Tissue Engineering, is a combination product featuring a human autologous epidermal cell sheet created using Green's technique. In December 2018, Japan's Ministry of Health, Labour and Welfare (MHLW) … tly the only FDA-approved therapy for RDEB wounds that works with just a single application. The approval was granted based on results from the Phase III VIITAL study (NCT04227106), a multi-center, randomized, intrapatient-controlled trial. The study successfully met its two main goals, showing significant wound healing (50% or more from baseline
Characterization of novel therapies for epidermolysis bullosa in clinical development: a cross-sectional analysis Characterization of novel therapies for epidermolysis bullosa in clinical development: a cross-sectional analysis Arch Dermatol Res . 2024 Jul 20;316(7):480. doi: 10.1007/s00403-024-03232-5. Authors Aaron Gabriel W Sandoval 1 2 , Heidi Kempinski 3 , Shelley Hartman 3 , Evangelos V Badiavas 3 4 Affiliations 1 Harvard Medical School, 25 Shattuck St, 02115, Boston, MA, USA. [email protected]. 2 Aegle Therapeutics, Wob
Evangelos V. Badiavas - Inventor, Founder & Chief Scientific Officer at Aegle Therapeutics | The Org Platform Enrich Pricing Log in Sign up Aegle Therapeutics Evangelos V. Badiavas Unverified Evangelos V. Badiavas Inventor, Founder & Chief Scientific Officer Contact Aegle’s research team is headed by Dr. Badiavas—a board certified dermatologist and dermatopathologist—whose research has been focused on wound healing, bone marrow, stem cells, bioengineered skin, dermatology, and translational research for more than 30 years. Dr. Badiavas was among the first to describe the trafficking … iavas has completed his PhD, postdoctoral training, medical school, dermatology residency, and dermatopathology fellowship. He is a practicing dermatologist and dermatolopathologist with more than 20 years experience with particular interests in the histologic evaluation of wounds. He has been working with bioengineered skin materials for more than 25 years and has described several key histological features associated with the application of these materials to patients. Dr.
Aegle Therapeutics Show navigation Company About Us Management Board of Directors Extracellular Vesicle Therapy Extracellular Vesicle Therapy Technology References PIPELINE Epidermolysis Bullosa Burns Aegle’s Platform News CONTACT >> --> Management Team Shelley A. Hartman Chief Executive Officer Shelley Hartman has served as the Chief Executive Officer of Aegle Therapeutics since August of 2014 and became Chairman of the Board in January 2020. Prior to Aegle, Ms. Hartman served for nine years as CEO of LifeSync Corporation, a start-up medical device company developing and marketing wireless me … iavas has completed his PhD, postdoctoral training, medical school, dermatology residency, and dermatopathology fellowship. He is a practicing dermatologist and dermatolopathologist with more than 20 years experience with particular interests in the histologic evaluation of wounds. He has been working with bioengineered skin materials for more than 25 years and has described several key histological features associated with the application of these materials to patients. Dr.
Dr. Evangelos Badiavas, MD – Miami, FL | Dermatology Skip to main content Evangelos Van Badiavas MD Dermatology • Miami , FL Dermatopathology Professor, Dermatology & Cutaneous Surgery, University of Miami Leonard M. Miller School of Medicine Join to View Full Profile 1295 NW 14th St Miami, FL 33125 Phone +1 305-243-6704 Dr. Badiavas is on Doximity As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network. Gain access to free telehealth tools, such as our “call s … an account? Education & Training University of Miami/Jackson Health System Fellowship, Dermatopathology, 1994 - 1995 University of Miami/Jackson Health System Residency, Dermatology, 1991 - 1994 Drexel University College of Medicine/Hahnemann University Hospital Internship, Internal Medicine, 1990 - 1991 Sidney Kimmel Medical College at Thomas Jefferson University Class of 1990 The following disclaimer is related to board certifications obtained from ABMS®, denoted by th … Wasif N Khan, JAMA Press Mentions Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa January 8th, 2020 Grant Support Bone Marrow Stem Cells And The Microenvironment Of Chronic Wounds National Institute On Aging 2008–2011 P1: Potential Of Skin Stem Cells And Wound Healing National Center For Research Resources 2007–2008 Bone Marrow Stem Cells And The Microenvironment Of Chr … pp Op-Med Research Directory Terms of Service Privacy Partners Partner Overview Residency Navigator Developer API Hiring Solutions Hospital Solutions Help © 2026 Doximity, Inc. iPhone and iPad are trademarks of Apple Inc., registered in the U.S. and other countries.
Company - AEGLE Therapeutics Company EV Therapy Pipeline News Contact Company Aegle Therapeutics is developing novel therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells (MSCs) to deliver therapeutic biomolecules to diseased and damaged cells to treat disorders with significant unmet medical need. EVs are the body’s courier service. MSCs, like all cells, package cell specific cargo into membrane bound EVs and then release the EVs. MSC-EVs travel in the intracellular space or in the bloodstream to recipient cells, delivering contents such as nucleic acids, proteins … d Managing Director and as Portfolio Manager of the JP Morgan Global Healthcare Fund. He currently serves on the board of directors for Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, Caribou Biosciences, Inc., a clinical-stage CRISPR genome-editing biopharmaceutical company, RAPT Therapeutics, Inc. (Nasdaq: RAPT), and Site One Therapeutics, a clinical-stage neurology company that is being acquired by Eli Lilly. Dr. Braunstein previously served on the boa … oulder is General Partner of Tellus BioVentures, LLC, a life science investment fund he founded in 2019. Previously Mr. Moulder was the co-founder, Chief Executive Officer and a member of the board of directors of TESARO, Inc., a public oncology-focused biopharmaceutical company that was acquired by GlaxoSmithKline plc. Previously Mr. Moulder served as Vice Chairman of the board of directors, President and Chief Executive Officer of Abraxis BioScience, Inc., a biotechnology c
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle Therapy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Dev … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle Therapy January 8, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Aegle Therapeutics Corp., a leader in the development of … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Thera … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board July 16, 2025 | 3 min read Twitter LinkedIn Facebook Email Print BOSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies … Healthcare Analyst and the Portfolio Manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein has been an operating partner at Aisling Capital since 2015. He currently serves on the board of directors for atai Life Sciences N.V., Caribou Biosciences, Inc., RAPT Therapeutics and Site One Therapeutics, a clinical-stage neurology company that is being acquired by Eli Lilly. Dr. Braunstein previously served on the board of directors of Trevena Inc., Esperion Therapeutics, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Clinical Trial Administering a Novel Extracellular Vesicle Therapy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Clinical Trial Administering a Novel Extracellular Vesicle Therapy August 16, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Aegle Therapeutics Corp. today announced the first patient has been dosed in the P … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA FDA Grants Fast Track Status to Aegle Therapeutics’ AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa October 1, 2020 | 1 min read Twitter LinkedIn Facebook Email Print Aegle Therapeutics Corporation today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track de … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Aegle Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA Aegle Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa October 6, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Aegle Therapeutics Corporation , a first-in-class biotechnol … ial and regenerative healing factors to diseased and damaged tissue. "The FDA's grant of Rare Pediatric Disease designation following its earlier grant of Fast Track Designation to AGLE-102 for DEB underscores the significant unmet medical need of children and adults living with this debilitating disease. AGLE-102 has the potential to be the first multifaceted approach to treat this rare patient population," said Shelley Hartman , CEO of Aegle Therapeutics. The FDA … ounger and fewer than 200,000 persons in the U.S. If Aegle's new drug application ("NDA") for DEB is approved, Aegle may receive a priority review voucher from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application or may be sold to another company for their programs. About Dystrophic Epidermolysis Bullosa DEB is a debilitating, genetic, pediatric disease characterized by skin fragility that can result in widespread blister … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102™ in Patients with Dystrophic Epidermolysis Bullosa ("DEB") - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developme … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102™ in Patients with Dystrophic Epidermolysis Bullosa (“DEB”) August 14, 2024 | 2 min read Twitter LinkedIn Facebook Email Print AGLE-102 is a novel extracellular vesicle therapy being developed for the treatment of rare a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Aegle Therapeutics Announces Award of Grant by U.S. Department of Defense's ("DoD") Congressionally Directed Medical Research Programs ("CDMRP") for Development of AGLE-102 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Aegle Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of AGLE-102 October 8, 2020 | 1 min read Twitter LinkedIn Facebook Email Print Aegle Therapeutics Corporation, a first-in-cl … llular vesicles as therapy, today announced that the Company has been awarded a grant by the U.S. BOSTON and MIAMI , Oct. 8, 2020 /PRNewswire/ -- Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced that the Company has been awarded a grant by the U.S. DoD's CDMRP to fund the continued development of the Company's product candidate AGLE-102™. The grant will support clinical manufacturi … f a phase 1 clinical study in burn patients. "The awarding of this grant is an important step in advancing Aegle's AGLE-102 as a potential therapy to treat severe burns," commented Evangelos Badiavas, Aegle's Chief Scientific Officer. "AGLE-102's unique properties and mechanism of action make it a potentially promising choice for clinical evaluation in this area of high unmet medical need." "We are honored to be selected for this award from the U.S. DoD," said Sh … om the U.S. DoD," said Shelley Hartman , Aegle's Chief Executive Officer. "This grant will enable us to advance the clinical development of AGLE-102 as a potential treatment for both military and civilian burn patients alike." About Aegle Therapeutics Corporation Aegle Therapeutics ( www.aegletherapeutics.com ) is a privately held biotechnol
Harnessing the regenerative, immunomodulatory, and anti-inflammatory potential of MSC-derived Extracellular Vesicles - AEGLE Therapeutics Company EV Therapy Pipeline News Contact Harnessing the regenerative, immunomodulatory, and anti-inflammatory potential of MSC-derived Extracellular Vesicles Aegle Therapeutics is a pioneer in regenerative medicine developing extracellular vesicle (EV) therapy to meaningfully improve the lives of those suffering from debilitating rare diseases, including dystrophic epidermolysis bullosa (DEB) and other severe dermatological disorders. Aegle’s platform techno
%PDF-1.5 %���� 1132 0 obj > endobj xref 1132 191 0000000016 00000 n 0000006629 00000 n 0000006746 00000 n 0000009441 00000 n 0000010641 00000 n 0000010904 00000 n 0000012245 00000 n 0000013449 00000 n 0000015260 00000 n 0000016581 00000 n 0000016696 00000 n 0000017769 00000 n 0000017886 00000 n 0000017982 00000 n 0000019184 00000 n 0000020525 00000 n 0000022336 00000 n 0000023543 00000 n 0000024667 00000 n 0000025443 00000 n 0000026420 00000 n 0000027242 00000 n 0000027391 00000 n 0000027788 00000 n 0000027827 00000 n 0000028003 00000 n 0000028329 00000 n 0000029507 00000 n 0000030246 00000 n … �� endstream endobj 1224 0 obj > endobj 1225 0 obj > endobj 1226 0 obj >stream application/postscript Print (Daniel Elliott) 2024-04-18T10:07:42+01:00 2024-04-18T10:07:42+01:00 2024-04-18T10:07:42+01:00 Adobe Illustrator 28.4 (Macintosh) xmp.iid:ebfdda4d-7158-4935-b5e1-a7392be9853e xmp.did:e11a2ffb-bea2-4a9a-aab2-7be668b97b6a uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:f477091f-e84f-4961-ad57-7e51b9533c86 xmp.did:f477091f-e84f-4961-ad57-7e51b9533c86 uuid:5D208924 … 019-04-01T13:47:14+01:00 Adobe Illustrator CC 23.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:0508f050-4d78-44e5-8a04-3ad022a8782e 2021-07-16T09:05:33+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:eecd9456-79ce-4589-920a-ca217ecb2b5c 2022-03-09T16:37:51Z Adobe Illustrator 26.0 (Macintosh) / converted from application/postscript to a … 0 2022-04-26T11:40:45+01:00 Adobe Illustrator 26.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:d95e4b86-972c-41d4-8d10-c93cfe4f75c4 2023-03-15T09:27:46Z Adobe Illustrator 27.3 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3d495f76-9b71-4f61-b4b0-4a77d715cff0 2024-03-11T09:31:28Z Adobe Ill … 533c86 2024-03-11T09:32:15Z Adobe Illustrator 28.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:e11a2ffb-bea2-4a9a-aab2-7be668b97b6a 2024-04-18T10:07:42+01:00 Adobe Illustrator 28.4 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from appl
Welcome to the 7th Exosome-Based Therapeutic Development Summit | pharmaphorum Skip to main content Friday 26 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research &
Aegle Therapeutics - Exosomebased Therapeutics Skip to content September 22-24, 2026 | Boston, MA About About Event Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Pre-Conference Day Day One Day Two Why Partner Why Partner Partnership Prospectus Partners Media Partners Take Part Pricing & Registration Venue & Accommodation Poster Session Contact Us Event Guide Register About About Event Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Pre-Conference Day Day One Day Two Why Partner Why Partner Partnership Prospectus Partners Media Partners
Aegle Therapeutics Careers | Levels.fyi Download App Change Login Sign Up All Data By Location By Company By Title Salary Calculator Chart Visualizations Verified Salaries Internships H-1B Salaries Negotiation Support Compare Benefits Who's Hiring 2025 Pay Report Top Paying Companies Integrate Blog Press Google Software Engineer Product Manager New York City Area Data Scientist Explore By Different Titles Levels FYI Logo Salaries 📂 All Data 🌎 By Location 🏢 By Company 🖋 By Title 🏭️ By Industry 📍 Salary Heatmap 📈 Chart Visualizations 🗺️ Atlas 🔥 Real-time Percentiles 🎓 Internships … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Featured Jobs No featured jobs found for Aegle Therapeutics Related Companies LinkedIn Spotify Intuit Databricks Snap See all companies ➜ Other Resources End of Year Pay Report Calculate Total Comp Featured Jobs No featured jobs found for Aegle Therapeutics Related Companies LinkedIn Spotify Intuit Databricks Snap See all companies ➜ Other Resources End of Year Pay Report Calculate Total Co